ID   LAMA-84
AC   CVCL_0388
SY   Lama-84; LAMA84; Lama84
DR   BTO; BTO:0004465
DR   CLO; CLO_0007238
DR   MCCL; MCC:0000283
DR   CLDB; cl3168
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473363
DR   BioSample; SAMN10988484
DR   cancercelllines; CVCL_0388
DR   CCRID; 1101HUM-PUMC000685
DR   Cell_Model_Passport; SIDM00346
DR   ChEMBL-Cells; CHEMBL3308267
DR   ChEMBL-Targets; CHEMBL2366090
DR   CLS; 300261
DR   Cosmic; 787500
DR   Cosmic; 907783
DR   Cosmic; 1012081
DR   Cosmic; 1019834
DR   Cosmic; 1026569
DR   Cosmic; 1078729
DR   Cosmic-CLP; 907783
DR   DepMap; ACH-000301
DR   DSMZ; ACC-168
DR   DSMZCellDive; ACC-168
DR   EGA; EGAS00001000978
DR   GDSC; 907783
DR   GEO; GSM887262
DR   GEO; GSM888337
DR   GEO; GSM1670031
DR   IARC_TP53; 21457
DR   LiGeA; CCLE_403
DR   LINCS_LDP; LCL-1109
DR   Lonza; 961
DR   Millipore; SCC140
DR   PharmacoDB; LAMA84_818_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0388
DR   PubChem_Cell_line; CVCL_0388
DR   Wikidata; Q54901914
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3476310;
RX   PubMed=7996872;
RX   PubMed=8693292;
RX   PubMed=9257809;
RX   PubMed=10071072;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=20809971;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: 48 hours (PubMed=3476310); 36 hours (PubMed=25984343); ~50 hours (DSMZ=ACC-168).
CC   HLA typing: A*02:01:01,25:01:01; B*18:01:01,44:02:01; C*05:01:01,12:03:01; DPA1*01:03:01,02:01:01; DQB1*06:02:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-168).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=14.08%; Native American=0%; East Asian, North=1.13%; East Asian, South=1.46%; South Asian=1.64%; European, North=29.64%; European, South=52.05% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): CCRID; CLS; Cosmic-CLP; DSMZ; Millipore
ST   Amelogenin: X
ST   CSF1PO: 8,11,12 (DSMZ)
ST   CSF1PO: 11,12 (CCRID; Cosmic-CLP; Millipore)
ST   CSF1PO: 11,12,13 (CLS)
ST   D12S391: 18,24
ST   D13S317: 11 (CLS; Cosmic-CLP; DSMZ; Millipore)
ST   D13S317: 11,12 (CCRID)
ST   D16S539: 11
ST   D18S51: 13
ST   D19S433: 13
ST   D1S1656: 15,15.3
ST   D21S11: 29,30,31 (CLS; DSMZ)
ST   D21S11: 29,31 (CCRID; Millipore)
ST   D2S1338: 17 (CLS; DSMZ)
ST   D2S1338: 17,19 (CCRID)
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D6S1043: 10,20
ST   D7S820: 11
ST   D8S1179: 10,15
ST   FGA: 21,22
ST   Penta D: 10
ST   Penta E: 7
ST   TH01: 6,7
ST   TPOX: 10 (CLS; Cosmic-CLP; DSMZ)
ST   TPOX: 10,11 (CCRID; Millipore)
ST   vWA: 14,17
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 41
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3476310;
RA   Seigneurin D., Champelovier P., Mouchiroud G., Berthier R., Leroux D.,
RA   Prenant M., McGregor J., Starck J., Morle F., Micouin C.,
RA   Pietrantuono A., Kolodie L.;
RT   "Human chronic myeloid leukemic cell line with positive Philadelphia
RT   chromosome exhibits megakaryocytic and erythroid characteristics.";
RL   Exp. Hematol. 15:822-832(1987).
//
RX   PubMed=7996872; DOI=10.1016/0145-2126(94)90102-3;
RA   Champelovier P., Valiron O., Jacrot M., Leroux D., Seigneurin D.;
RT   "Selection and characterization of an erythroeosinophilic subclone
RT   (LAMA-87) and an eosinophilic subclone (LAMA-88) from the
RT   multipotential cell line LAMA-84.";
RL   Leuk. Res. 18:903-918(1994).
//
RX   PubMed=8693292; DOI=10.1046/j.1365-3083.1996.d01-84.x;
RA   Blom T., Nilsson G., Sundstrom C., Nilsson K., Hellman L.;
RT   "Characterization of a human basophil-like cell line (LAMA-84).";
RL   Scand. J. Immunol. 44:54-61(1996).
//
RX   PubMed=9257809;
RA   Champelovier P., Fixe P., Valiron O., Feige J.-J., Praloran V.,
RA   Seigneurin D.;
RT   "Proliferation of LAMA-84 and LAMA-87 cell lines is modulated by
RT   autocrine loops involving M-CSF and TGF-beta.";
RL   Exp. Hematol. 25:958-965(1997).
//
RX   PubMed=10071072; DOI=10.1016/s0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20809971; DOI=10.1186/1755-8166-3-15;
RA   Virgili A., Nacheva E.;
RT   "Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in
RT   chronic myeloid leukaemia: a FISH mapping study of CML patients and
RT   cell lines.";
RL   Mol. Cytogenet. 3:15.1-15.12(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//